HAMMERSMITH MEDICINES RESEARCH LIMITED
Get an alert when HAMMERSMITH MEDICINES RESEARCH LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-07-31 (in 2mo)
Last filed for 2024-01-31
Confirmation statement due
2027-01-29 (in 8mo)
Last made up 2026-01-15
Watchouts
Cash
£4M
+88.1% vs 2023
Net assets
£24M
-3% vs 2023
Employees
291
-5.5% vs 2023
Profit before tax
-£1M
+50.8% vs 2023
Watchouts
Facts from the Companies House register and the latest accounts — not a rating
-
Material uncertainty over going concern
We draw attention to Note 2 in the financial statements, which explains that the group has experienced a decline in new trials after the year end, resulting in significant cashflow issues. As stated in Note 2, these circumstances along with other matters referred to in Note 2 give rise to a material uncertainty that may cast significant doubt on the group's ability to continue as a going concern. Our opinion is not modified in respect of this matter.
-
Audit opinion: Qualified
Latest auditor's report carried a non-clean opinion.
-
1 PSC ceased in last 24 months
Significant control changed hands — see the Ownership section.
Net assets
5-year trend · vs Industrials median
Accounts
5-year trend · latest reflected 2024-01-31
| Metric | Trend | 2020-01-31 | 2021-01-31 | 2022-01-31 | 2023-01-31 | 2024-01-31 |
|---|---|---|---|---|---|---|
| Turnover | — | — | — | £20,614,693 | £21,477,373 | |
| Operating profit | — | — | — | -£2,048,908 | -£1,095,393 | |
| Profit before tax | — | — | — | -£2,089,927 | -£1,027,864 | |
| Net profit | — | — | — | -£1,396,931 | -£729,203 | |
| Cash | — | — | — | £1,985,589 | £3,735,190 | |
| Total assets less current liabilities | — | — | — | £26,434,610 | £25,573,136 | |
| Net assets | — | — | — | £24,394,700 | £23,665,497 | |
| Equity | £25,617,096 | £25,142,067 | £25,726,238 | £24,394,700 | £23,665,497 | |
| Average employees | — | — | — | 308 | 291 | |
| Wages | — | — | — | £11,479,669 | £11,563,952 | |
| Directors' remuneration | — | — | — | £70,912 | £121,863 |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Year-on-year
FY2023 → FY2024 · period ending 2024-01-31 vs 2023-01-31
-
Turnover
+4.2%
£20,614,693 £21,477,373
-
Cash
+88.1%
£1,985,589 £3,735,190
-
Net assets
-3%
£24,394,700 £23,665,497
-
Employees
-5.5%
308 291
-
Operating profit
+46.5%
-£2,048,908 -£1,095,393
-
Profit before tax
+50.8%
-£2,089,927 -£1,027,864
-
Wages
+0.7%
£11,479,669 £11,563,952
Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2020-01-31 | 2021-01-31 | 2022-01-31 | 2023-01-31 | 2024-01-31 |
|---|---|---|---|---|---|---|
| Operating margin | — | — | — | -9.9% | -5.1% | |
| Net margin | — | — | — | -6.8% | -3.4% | |
| Return on capital employed | — | — | — | -7.8% | -4.3% | |
| Current ratio | — | — | — | 6.25x | 5.74x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Name history
Renamed 1 time since incorporation
- HAMMERSMITH MEDICINES RESEARCH LIMITED 1995-02-06 → present
- HAMMERSMITH MEDICAL RESEARCH LIMITED 1993-01-15 → 1995-02-06
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Consolidated group
- Auditor
- Hartley Fowler LLP
- Audit opinion
- Qualified
- Going concern
- Material uncertainty disclosed
“We draw attention to Note 2 in the financial statements, which explains that the group has experienced a decline in new trials after the year end, resulting in significant cashflow issues. As stated in Note 2, these circumstances along with other matters referred to in Note 2 give rise to a material uncertainty that may cast significant doubt on the group's ability to continue as a going concern. Our opinion is not modified in respect of this matter.”
Group structure
- HAMMERSMITH MEDICINES RESEARCH LIMITED · parent
- Trio Medicines Limited 100%
- Hammersmith Medicines Research (Properties) Limited 100%
Significant events
- “Exceptional items in the year were comprised of settlement fees for legal claims against the company in relation to the data breach that occurred in March 2020.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
2 active · 6 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| PISAREV, Teena Joy | Director | 2025-08-01 | Sep 1974 | Australian |
| WOOD, Graham Keith | Director | 2025-08-01 | May 1972 | Canadian |
Show 6 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| O'BRIEN, Charles Kevin | Secretary | 1995-01-15 | 2025-01-31 |
| APPLETON SECRETARIES LIMITED | Corporate Nominee Secretary | 1993-01-15 | 1995-01-15 |
| BOYCE, Malcolm James, Dr | Director | 1993-01-18 | 2025-08-01 |
| SMITH, Russell, Professor | Director | 2012-08-07 | 2013-10-18 |
| WARRINGTON, Steven John, Dr | Director | 1996-01-26 | 2025-08-01 |
| APPLETON DIRECTORS LIMITED | Corporate Nominee Director | 1993-01-15 | 1993-01-18 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Nn Bidco Pty Ltd (Acn 623 536 247) | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2025-08-01 | Active |
| Dr Malcolm James Boyce | Individual | Shares 75–100% | 2016-04-06 | Ceased 2025-08-01 |
Filing timeline
Last 20 of 91 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-04-08 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-10-28 | AA01 | accounts | Change account reference date company previous extended | |
| 2025-08-06 | PSC07 | persons-with-significant-control | Cessation of a person with significant control | |
| 2025-08-06 | PSC02 | persons-with-significant-control | Notification of a person with significant control | |
| 2025-08-06 | TM01 | officers | Termination director company with name termination date | |
| 2025-08-06 | TM01 | officers | Termination director company with name termination date | |
| 2025-08-06 | AP01 | officers | Appoint person director company with name date | |
| 2025-08-06 | AP01 | officers | Appoint person director company with name date | |
| 2025-05-21 | AA | accounts | Accounts with accounts type group | |
| 2025-01-31 | TM02 | officers | Termination secretary company with name termination date | |
| 2025-01-17 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-04-24 | AA | accounts | Accounts with accounts type group | |
| 2024-01-22 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-04-25 | AA | accounts | Accounts with accounts type group | |
| 2023-04-12 | DISS40 | gazette | Gazette filings brought up to date | |
| 2023-04-04 | GAZ1 | gazette | Gazette notice compulsory | |
| 2023-01-25 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2022-02-01 | AA | accounts | Accounts with accounts type group | |
| 2022-01-17 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2021-02-09 | AA | accounts | Accounts with accounts type group |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 9
- Capital events
- 0
- Officers appointed
- 2
- Officers resigned
- 2
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.